Perianal Fistula Clinical Trial
Official title:
Randomized Clinical Trial for the Treatment of Lower Transsphincteric Perianal Fistula Using Fistulotomy With Marsupialization vs Open Wound
NCT number | NCT04722965 |
Other study ID # | CSAPG-13 |
Secondary ID | |
Status | Withdrawn |
Phase | N/A |
First received | |
Last updated | |
Start date | April 1, 2021 |
Est. completion date | July 1, 2023 |
Verified date | March 2024 |
Source | Consorci Sanitari de l'Alt Penedès i Garraf |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will compare the results of marsupialization versus open wound after fistulotomy in low transsphincteric perianal fistulas.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | July 1, 2023 |
Est. primary completion date | February 1, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Low transsphinteric perianal fistula, defined as a single tract in the lower third of the anal sphincter, confirmed by ultrasound and intraoperative evaluation. - Ability to understand the study, to sign the consent and to complete the follow-up. Exclusion Criteria: - Under 18 years of age. - Complex/recurrent fistula. - Patients in which by clinical criteria is decided not to perform a fistulotomy. - Anorectal malignancy. - Crohn's desease. - ASA IV or other contraindication for surgery. - Inmunosuppressed patients or in treatment with steroids or cytotoxic drugs. |
Country | Name | City | State |
---|---|---|---|
Spain | Consorci Sanitari Alt Penedes i Garraf | Sant Pere De Ribes | Barcelona |
Lead Sponsor | Collaborator |
---|---|
Consorci Sanitari de l'Alt Penedès i Garraf |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Wound healing time | Comparisson of the time it takes for the wound to not have areas without epithelium after the fistulotomy between the group with marsupialization and the open wound group. | 6 weeks | |
Secondary | Postoperative pain | Maximum pain experienced by the patient in the postoperative period measured by the visual scale of pain. | 6 weeks | |
Secondary | Return to daily activities | Days it takes the patients to return their daily activities (e.g. job). | 6 weeks | |
Secondary | Operating time | Time the surgery takes since the assessment of the fistula tract to the beginning of dressing of the postoperative wound. It's measured in minutes. | 60 minutes | |
Secondary | Hospitalization time | Days the patient has to stay admitted in the hospital. | 2 days | |
Secondary | Bleeding of the postoperative wound | Number of bleeding episodes that require more changing of the dressings or assistance of a medical professional. | 6 weeks | |
Secondary | Anal incontinence | Postoperative anal incontinence measured by the Browning and Parks incontinence scale: I: normal continence, II: Continent for solid and liquid stools but not for flatus, III: Continent for solid stools only, IV: Complete incontinence. | 6 weeks | |
Secondary | Frequency of dressing change | Number of times per day a patient needs a dressing change | 6 weeks | |
Secondary | Who performs the dressing change | Indicate who performs the dressing change: Patient, family member or medical professional. | 6 weeks | |
Secondary | Postoperative wound infection | Presence of erythema, induration surrounding the wound or suppuration with or without an isolated pathogenic microorganism. | 6 weeks | |
Secondary | Recurrence of the fistula | Reappearance of the fistula after complete healing of the surgical wound within the period of the study. | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03913572 -
Treatment of Perianal Disease Using Adipose-derived Stem Cells
|
||
Terminated |
NCT01623453 -
Follow-up Study of Autologous Adipose-derived Stem Cells (ANTG-ASC) for the Complex Fistula (ANTG-ASC-211)
|
N/A | |
Completed |
NCT06441526 -
Surgical Closure vs Anti-TNF in the Treatment of Perianal Fistulas in Crohn's Disease (PISA-II): a Comprehensive Cohort Design
|
Phase 3 | |
Recruiting |
NCT04847739 -
Seeded Cells on Matrix Plug Treating Crohn's Perianal Fistulas (STOMP-II)
|
Phase 2 | |
Completed |
NCT06314945 -
Diagnostic Value of Recto-perineal Ultrasound in Perianal Fistula
|
||
Completed |
NCT03763981 -
Comparison of Prolene Thread Seton Vs Silk Thread Seton for the Treatment of Perianal Fistula
|
N/A | |
Not yet recruiting |
NCT05626023 -
A Study of Human TH-SC01 Cell Injection for Treating Perianal Fistulas in Patients With Crohn's Disease
|
Phase 1/Phase 2 | |
Completed |
NCT01021774 -
Anal Fistula Treatment Outcome - Collagen Plug Versus Advancement Flap Surgery
|
N/A | |
Recruiting |
NCT04519671 -
Mesenchymal Stem Cells for the Treatment of Perianal Fistulizing Crohn's Disease
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04549311 -
Perianal Abscess Recurrence and Fistula Formation: Antibiotics Following Incision and Drainage Trial
|
Phase 3 | |
Completed |
NCT03555773 -
Micro-fragmented Adipose Tissue and Complex Crohns' Anal Fistulas
|
N/A | |
Recruiting |
NCT03707769 -
TIPS Microspheres for Perianal Fistula
|
N/A | |
Completed |
NCT03803917 -
Adipose Tissue in Crohn´s Disease Fistulas
|
N/A | |
Recruiting |
NCT03322488 -
Fistulodesis Pilot Study for Closure of Perianal Fistulae
|
N/A | |
Withdrawn |
NCT03014219 -
Phase 1 Crohn's Pediatric Sub-study of MSC AFP
|
Phase 1 | |
Completed |
NCT03209700 -
Re-treatment From a Phase I Study of MSC-AFP in Patients With Perianal Fistulas
|
Phase 1 | |
Completed |
NCT03981939 -
Perianal Fistula (PAF) Validation and Burden of Illness Study
|
||
Recruiting |
NCT05721794 -
Comparative Accuracy of Transperineal Ultrasound (TPUS) Versus Magnetic Resonance Imaging (MRI) for the Assessment of Perianal Fistulae in Patients With Crohn's Disease (CD): a Prospective Observational Longitudinal Cohort Study
|
||
Enrolling by invitation |
NCT03861689 -
Tight Control Management in Perianal Crohn's Disease
|
N/A | |
Not yet recruiting |
NCT05709717 -
Regenerative Therapy With Autologous Stromal Vascular Fraction Derived Mesenchymal Stem Cells and Platelet-rich Plasma to Treat Complex Perianal Diseases
|